Ophthalmologists attending The Australasian Society of Cataract and Refractive Surgeons (AUSCRS) annual conference, this year on the Sunshine Coast in Queensland, will be among the very first in Australia to discover RxSight’s Light Adjustable Lens (LAL).
Now available in Australia and New Zealand, the LAL is the first and only intraocular lens (IOL) that enables postoperative refractive customisation. Adjustable using targeted UV light treatments, the non-diffractive design also preserves contrast sensitivity while minimising dysphotopsias.1
The LAL, which has been developed over more than two decades, brings together advances in optics, material science, photochemistry and engineering. It received United States Food and Drug Administration (FDA) approval in November 2017, and United States commercialisation began in 2019.
Since then, more than 1,100 LALs have been installed, and over 325,000 LAL procedures performed worldwide.
Personalised Vision, Adjusted After Surgery
Cataract surgery and IOLs are constantly evolving, but one familiar challenge remains: with conventional IOLs, the final lens power is selected before surgery and cannot be changed after implantation. Even with careful measurements and surgical planning, healing patterns and subtle changes in effective lens position (ELP) can influence the final refractive result.
The LAL changes that conversation. It makes refractive refinement part of the treatment journey by allowing surgeons to adjust the implanted lens non-surgically after the eye has healed.
postoperative adjustability creates an opportunity to differentiate the patient experience while offering a more personalised approach to refractive outcomes
How the Light Adjustable Lens Works
At the core of the LAL is a photosensitive lens material containing special light-responsive macromers. Using the RxSight Light Delivery DeviceT (LDD), surgeons apply low intensity UV light to specific regions of the implanted lens.
The exposed macromers polymerise, while the remaining macromers migrate toward the treated area. This produces a highly predictable change in lens curvature and refractive power, enabling postoperative adjustments, tailored to the patient’s visual goals.
Why It Matters for Patients and Practices
The LAL gives patients the opportunity to participate in their visual outcome after surgery. Instead of committing to a fixed result before their eye has healed, patients can work with their surgeon to refine vision around the activities that matter most, from distance vision and driving to reading, work, and screen use.
For practices, postoperative adjustability creates an opportunity to differentiate the patient experience while offering a more personalised approach to refractive outcomes. It also opens meaningful conversations around precision, patient experience, and shared decision-making in modern cataract surgery.
Postoperative Adjustment Range
The UV light treatments can address both spherical and cylindrical refractive error in 0.25 D increments, correcting residual astigmatism as low as 0.50 D. This enables surgeons to postoperatively refine refractive outcomes with precision across distances while managing astigmatism within a single IOL platform. The non-diffractive design also preserves contrast sensitivity while minimising dysphotopsias, making it suitable for a broad range of patients.1
Clinical studies have demonstrated excellent refractive accuracy with the LAL, with a vast majority of patients achieving 20/20 vision or better, and landing within ±0.50 D of their intended target. 2,3
More Insights at AUSCRS
At AUSCRS, from 15 –18 July 2026, Dr Baseer Khan will share his clinical experience with the LAL in two presentations. He will present ‘Optimising outcomes with the LAL in high-volume practices’ in the doctor’s program and “Redefining cataract outcomes: Introducing postoperative adjustability with the LAL” in the support staff program.
Additionally, Professor Michael Knorz will explore how the IOL performs in more complex cases in a presentation titled ‘The LAL in post-LASIK eyes’.
AUSCRS takes place at the Novotel on the Sunshine Coast from 15 –18 July, 2026. Visit Booth 29 at AUSCRS to meet the team, experience a live demonstration of the LDD, and join the silent disco booth talks to find out more.
Contact: contact_globalmarketing@rxsight.com.
#Sponsored content
References
- RxSight P160055: FDA summary of safety and effectiveness data. 2017. Available at accessdata.fda.gov/cdrh_docs/pdf16/P160055b.pdf.
- Sandoval HP, Donnenfeld ED, Solomon KD, et al. Modern laser in situ keratomileusis outcomes. J Cataract Refract Surg. 2016 Aug;42(8):1224-34. doi: 10.1016/j.jcrs.2016.07.012.
- Wong JR, Folden DV, Johnson R, et al. Visual outcomes of a second-generation, enhanced UV protected light adjustable lens in cataract patients with previous LASIK and/or PRK. Clin Ophthalmol. 2023 Nov 6;17:3379-3387. doi: 10.2147/OPTH.S432457.
